title: Neuroprotective effects of  NEP1-40 and fasudil on Nogo-A expression in neonatal rats with hypoxic-ischemic  brain damage.
abstract: The  hypoxic-ischemic encephalopathy caused by peripartum asphyxia is a serious  disease in newborn infants, and effective therapies need to be developed to  reduce injury-related disorders. We evaluated the effects of NEP1-40 and  fasudil on Nogo-A expression in neonatal hypoxic-ischemic brain damage (HIBD)  rats. Seven-day-old Wistar rats were randomly divided into control, HIBD,  NEP1-40, and fasudil groups. NEP1-40 and fasudil groups were injected  intraperitoneally with these compounds. Rat brains at 6, 24, 72 h, and 7 days  after HIBD were collected to determine histopathological damage and the  expression levels of Nogo-A. Histopathological damage was reduced in NEP1-40  and fasudil groups compared with the untreated HIBD group. The expression of  Nogo-A in the HIBD group was significantly higher than that in control, NEP1-40  and fasudil groups at the same times. Compared with the fasudil group, the  expression levels of Nogo-A were significantly reduced in the NEP1-40 group. We  conclude that NPE1-40 and fasudil have potential for neuroprotective effects in  the neonatal rat HIBD model, mediated by inhibiting Nogo-A/ Rho pathways.
authors.affiliation: Department of Pediatrics, Jinan Central Hospital Affiliated to Shandong University, Jinan, P.R. China. jnzxyyzhww@yahoo.com.cn
authors.forename: W W
authors.initials: WW
authors.lastname: Zhu
authors.forename: X L
authors.initials: XL
authors.lastname: Ma
authors.forename: A L
authors.initials: AL
authors.lastname: Guo
authors.forename: H Y
authors.initials: HY
authors.lastname: Zhao
authors.forename: H H
authors.initials: HH
authors.lastname: Luo
mesh_terms: D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D000831:Animals, Newborn; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D002339:Carotid Arteries / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D005260:Female; D015870:Gene Expression / Q000187:drug effects; D020925:Hypoxia-Ischemia, Brain / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D007274:Injections, Intraperitoneal; D008026:Ligation / Q000379:methods; D008297:Male; D009185:Myelin Proteins / Q000008:administration & dosage / Q000096:biosynthesis* / Q000235:genetics / Q000627:therapeutic use*; D009474:Neurons / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000070798:Nogo Proteins; D010446:Peptide Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D009185:Myelin Proteins; C509624:NEP1-40 protein, human; D018696:Neuroprotective Agents; D000070798:Nogo Proteins; D010446:Peptide Fragments; C000603199:RTN4 protein, human; C000603197:Rtn4 protein, rat; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; C049347:fasudil